Research at Design Therapeutics Inc. has led to the discovery of conjugates consisting of a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence linked to a protein binding moiety through oligomeric backbone linker. They are transcription modulators reported to be useful for the treatment of Huntington’s disease.

Voronoi and Voronoi Bio Inc. have patented serine/threonine-protein kinase B-raf (BRAF), Raf kinase and Raf kinase B (V600E mutant) inhibitors reported to be useful for the treatment of cancer.

Sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers have been reported in a Humanwell Healthcare (Group) Co. Ltd. patent as potentially useful for the treatment of pain.

Fusion Biotechnology and Ulsan National Institute of Science and Technology (UNIST) have prepared sugar-linked imidazoline derivatives and their micelles reported to be useful for the treatment of age-related diseases.

A University of Texas System patent describes new allosteric modulators of 5-HT2A and/or 5-HT2C receptors potentially useful for the treatment of obesity, substance abuse and dependence, mood and seizure disorders.

Takeda Pharmaceutical Co. Ltd. has identified N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives acting as somatostatin SST4 receptor agonists and thus reported to be useful for the treatment of Alzheimer’s disease, depression, schizophrenia, autism, epilepsy, pain, bipolar and anxiety disorder.

Morphinan derivatives acting as κ-opioid receptor agonists have been discovered by Toray Industries Inc. They are reported to be useful for the treatment of pain, hepatobiliary and hematologic diseases, cardiovascular and respiratory disorders.

Research at the University of Florida has led to the identification of compounds acting as dual dopamine transporter (DAT) and sigma receptor (sigma nonopioid intracellular receptor 1 [σ1, SIGMAR1] and sigma intracellular receptor 2 [σ2, TMEM97]) antagonists reported to be useful for the treatment of methamphetamine dependence and cocaine dependency.

Epoxysqualene-lanosterol cyclase (lanosterol synthase, OSLC) inhibitors have been reported in a University of Texas System patent as potentially useful for the treatment of amyotrophic lateral sclerosis, glioblastoma, multiple sclerosis, neurodegeneration, Parkinson’s, Alzheimer’s and Huntington’s diseases.

Escient Pharmaceuticals Inc. has patented quinoline derivatives acting as Mas-related G protein-coupled receptor member X2 (MRGPRX2) antagonists and thus reported to be useful for the treatment of pain, psoriasis, inflammatory disorders, atopic dermatitis, eczema, pruritus, urticaria and autoimmune disease, among others.